Skip to main content

Articles

Meeting USP Chapter 800 Head On
Meeting USP Chapter 800 Head On
By Michael Koraleski, PharmD
Conference Correspondent, Audiocast
Audiocasts
Michael Koraleski, PharmD, outlined the proposed standards of the newest US Pharmacopeial Convention (USP) Chapter 800 at the 11th annual Hematology/Oncology Pharmacy As­­sociation conference. Read More ›
Michael Koraleski, PharmD
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
By Wayne Kuznar
TOP - August 2015, Vol 8, No 3
The National Com­prehensive Cancer Network (NCCN) now recommends nivolumab (Opdivo) as subsequent therapy for metastatic squamous non–small-cell lung cancer (NSCLC) after its recent FDA approval. Read More ›
Wayne Kuznar
Stereotactic Body Radiation Therapy Shows Acceptable Urinary and Sexual Toxicity
By Chase Doyle
Genitourinary Cancers
TOP - August 2015, Vol 8, No 3
Although recent studies have shown the efficacy of using ster­eotactic body radiation therapy (SBRT) as a treatment modality for organ-confined prostate cancer, questions over urinary symptoms and sexual dysfunction have remained. Read More ›
Chase Doyle
Highlights from the 2015 Genitourinary Cancers Symposium
Conference Correspondent
TOP - August 2015, Vol 8, No 3
  • Abiraterone and Metabolic Syndrome
  • Obesity and Survival in Metastatic Renal-Cell Carcinoma
  • Radium-223 and Pain
  • New Biomarker for Survival
  • Quality of Life in Long-Term Survivors of Bladder Cancer
Read More ›
Developing a Pharmacist-Driven Drug-Monitoring Protocol
By Meg Barbor, MPH
Conference Correspondent
TOP - August 2015, Vol 8, No 3
A successful pharmacist-­driven drug-monitoring protocol can be achieved in a medical practice when necessary elements are considered. Read More ›
Meg Barbor, MPH
NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer
By Wayne Kuznar
TOP - August 2015, Vol 8, No 3
A new clinical guideline for smoking cessation in patients with cancer encourages the use of evidence-based pharmacotherapy, behavioral therapy, and close follow-up with retreatment. Read More ›
Wayne Kuznar
AONN+ Granted Membership in the American College of Surgeons Commission on Cancer
TOP - August 2015, Vol 8, No 3
The Academy of Oncology Nurse & Patient Navigators® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeons Commission on Cancer (CoC). Read More ›
Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future
By Wayne Kuznar
Hematologic Cancers
TOP - August 2015, Vol 8, No 3
In his NCCN update of the CLL guideline, Dr Wierda noted that the Bruton’s tyrosine kinase (BTK) inhibitor­ ibrutinib (Imbruvica) could soon replace conventional chemotherapy. Read More ›
Wayne Kuznar
From the Editors
By Patrick J. Medina, PharmD, BCOP; Steven Stricker, PharmD, MS, BCOP
From the Editors
TOP - August 2015, Vol 8, No 3
In this month’s issue of The Oncology Pharmacist, we present coverage of the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. We highlight presentations on the effectiveness of rolapitant for chemotherapy-induced nausea and vomiting, as well as data on the association between osteonecrosis of the jaw and medication. Read More ›
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
Noteworthy Numbers: Prostate Cancer
Noteworthy Numbers
TOP - August 2015, Vol 8, No 3
With the exception of skin cancer, prostate cancer is the most common cancer affecting men. Read More ›

Page 137 of 288